Targeting poly-gama-glutamic acid to treat Staphylococcus epidermidis and related infections
US8623371B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 20, 2012 |
| Grant date | Jan 7, 2014 |
| Priority date | — |
| Expiry date | Jul 20, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/77
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-γ-glutamic acid (such as γDLPGA) polypeptides of S. epidermidis, or related staphylococci that express a γPGA polypeptide. The γPGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagonosed with the infection by the Staphylococcus organism which expresses γPGA from the cap genes. Further, the expression of a γPGA polypeptide by the organism can then be altered.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.